BioNexus Gene Lab's revenue for the
three
months ended in Sep. 2024 was $2.63 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $9.26 Mil.
BioNexus Gene Lab's Revenue per Share for the
three
months ended in Sep. 2024 was $0.15.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.52.
Warning Sign:
BioNexus Gene Lab Corp revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioNexus Gene Lab was -24.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -22.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 119.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, BioNexus Gene Lab's highest 3-Year average Revenue per Share Growth Rate was 269.70% per year. The lowest was -22.60% per year. And the median was 234.70% per year.
BioNexus Gene Lab Revenue Historical Data
The historical data trend for BioNexus Gene Lab's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Revenue
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Revenue Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Revenue distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Revenue falls into.
BioNexus Gene Lab Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (NAS:BGLC) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioNexus Gene Lab Revenue Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 